Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.


Cash in as the "Alibaba Shockwave" Creates the World's First Trillion-Dollar Company

How many times have you been reading about a long-ago historical event – or been watching a documentary about it on the History Channel – and thought to yourself: “Wow, it would’ve been really cool to have actually been there to see this happen.”

I couldn’t agree more: As a big history buff myself, I find myself making that statement on a regular basis.

  • biotech stocks

  • Best Stocks to Buy: Cash In on a New $35 Billion Biotech Market best stocks to buy

    Each week our Money Morning experts dish out the latest profit plays - and asset-protection moves - for our Money Morning Members - all for free.

    Last week, Money Morning's best stocks to buy included five biotech picks. Four of them are blazing trails in immuno-oncology. Our fifth biotech pick has already tripled in value in the last six months, and it's not done yet.

    Aside from these biotech winners, we covered an ETF play on the European Central Bank's recent policy changes, the best stock in "unified computing," and a smart gold buy at a discount.

    Get these plus more of our latest, best stocks to buy.
  • Stocks to Buy: Intercept Pharma (Nasdaq: ICPT) Ready to Double 20140611-stocks-to-buy

    Usually the best stocks to buy have not already tripled in value within the past six months.

    But then there's Intercept Pharmaceuticals Inc. (Nasdaq: ICPT).

    This biotech stock soared more than 500% in two days on the news its innovative and promising hepatitis drug obeticholic acid, or OCA, had a trial stopped early because the drug met the goals of the study.

    Bulls have refused to be distracted by some negative news that has pushed the stock back under $300 in the meantime.

    The crazy thing is, Intercept Pharma could actually double from here...
  • The Secret to Making Money from Bioscience's "Scariest Event"

    In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs- down for an experimental drug as it makes its way through the regulatory process.

    Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.

    Perhaps the least  understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.

    But they're also among the most powerful.

    Here's what I mean, and how to play them profitably... Full Story

  • Seven Biotech Stocks to Watch Based on "Game-Changing" Cancer Treatment Updates best biotech investments 2014

    A number of promising cancer treatments were presented this week by key global pharmaceutical players at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) - which is why this is a key time of year to watch a specific group of biotech stocks.

    The event, which this year took place May 30 - June 3, is attended by thousands of renowned oncologists, researchers, analysts, and investors. It is unquestionably the most highly anticipated and most news-generating cancer research meeting of the year.

    ASCO can deliver a blockbuster, breakout drug that will not only lead to better cancer treatments, but one that will also bring in billions of dollars in revenue. Moreover, there's also the potential of a drug's developer becoming a profitable takeover target.

    Check out this list of biotech stocks to watch post-ASCO.
  • The Four Telltale Signs of a Bioscience "Blockbuster" in the Making

    The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.

    But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.

    They're like big, green, neon signs that say, "This is an important drug with incredible profit potential."

    And this is how you find them... Full Story

  • Why Tesaro (Nasdaq: TSRO) Stock Is Surging Today best biotech investments 2014

    Shares of Tesaro Inc. (Nasdaq: TSRO) stock were up 23% today (Monday) after the company announced that its drug rolapitant met the main goal of its third and final Phase 3 trial.

    According to Money Morning's BioScience Investment Specialist Ernie Tremblay, volatility like that of TSRO stock is common among biotech companies with late stage drug candidates.

    Here's what investors should expect from this hot biotech stock now...
  • Best Stocks to Buy Now: A Hot Biopharma, an Energy Sector Worth $2 Trillion, and More stocks to buy

    Our roundup of the best stocks to buy last week gave Money Morning Members more than a dozen plays in 2014's most profitable sectors.

    One pick involves a possible healthcare merger that would combine two industry titans. The duo would create an industry powerhouse with a market cap near $300 billion. Another play revolves around one of the most highly anticipated, and possibly biggest, initial public offerings ever. And a special report from our small-cap trading specialist showed readers a technique for uncovering investment winners today.

    Here they are – with more opportunities – in our latest Money Morning best stocks to buy list:
  • Stocks to Buy: Why This Biopharma Company Is a “Long-Term Profit Machine” 20140509-stocks-to-buy-CARA

    One strategy experts use when looking for the best biotech stocks to buy is finding companies with promising drug candidates that are close to receiving regulatory approval. When these drugs hit the market, they can bring in billions in revenue.

    When companies have multiple promising drugs in their product pipeline, they become even more attractive because they have more than one shot at finding a revenue blockbuster.

    That’s why Money Morning’s Defense & Tech Specialist Michael A. Robinson likes this biotech stock to buy now…
  • Stocks to Buy: This Botox Competitor Is Heading Toward Huge Profits 20140429_stocks-to-buy

    When Valeant Pharmaceuticals International Inc. (NYSE: VRX) and activist investor Bill Ackman made an unsolicited $46 billion bid to purchase Botox maker Allergan Inc. (NYSE: AGN) last week, investors got a glimpse of just how big the Botox market is globally.

    And that had us pointing to our "Stocks to Buy" list...

    Money Morning's Defense & Tech Specialist Michael A. Robinson has been recommending a biotech stock that develops similar specialty products for dermatological applications. And it could see huge gains soon...
  • Stocks to Buy: 95% Return Is Just the Start For This Biotech Play Lab worker

    Investors looking for stocks to buy in 2014 have had an abundance of new options as 94 companies have gone public this year, according to Renaissance Capital.

    The average return for those 94 companies since their IPO date is 9%. But some stocks have far outpaced the average, and are still at great buy-in points even after huge gains.

    Money Morning's Defense and Tech Specialist Michael Robinson has found a stock that still provides investors a great profit opportunity, even after posting a 95% return from its IPO date...
  • These Long-Term Profit Machines Just Went On Sale

    Market volatility has suddenly created some great opportunities, including those in the biotech sector.

    Supporting the inevitable ascent of the industry is the release of a steady stream of compounds that have helped them rack up billions in new revenue.

    Grab these long-term profit machines at a discount now.
  • Three Orphan Drug Stocks to Buy When the Biotech Market Is Down best biotech investments 2014

    There's no sugarcoating it: Biotech stocks have had a rough run in the past month.

    But when other investors are running for the hills, Money Morning experts are finding profit plays. With biotech stocks trading lower, there are excellent buy-in opportunities on valuable biotech companies.

    Orphan drugs offer some of the best profit plays in biotech as the have extremely lucrative markets cornered.

    And these three stocks to buy are the best orphan drug plays now...
  • There Is No Biotech Bubble; Here's the Real Story 20140331_IPO-bubble

    Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.

    But they're wrong; the market is simply in a period of adjustment.

    The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.

    The problem with that argument is, these analysts are using a mass of technical indicators to support it. Anyone who's followed start-up biotechs knows that's a fool's errand.
  • Finding the Blockbuster That Will Make You Rich In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year. It's the prize that every biotech hopes to win - and every biotech investor hopes to cash in on. So how do you spot one in the making? If the market suspects a drug candidate has blockbuster potential, catalysts (events like positive clinical study results and regulatory milestones) will give its manufacturer's share price a big, big boost. There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search... Full story...
  • The Secret Behind This Controversial Industry's Leader

    As a long-time tech-investing analyst, I have one of the best vantage points in the country for tracking profitable marijuana industry trends.

    Here's the thing: I live 10 minutes from the epicenter of the medical marijuana movement in northern California, and the rest of the nation for that matter.

    Downtown Oakland contains a small cannabis-friendly district known as "Oaksterdam." In fact, there's a patient co-op across the street from a store where I buy my fedoras.

    I bring all this up so you know I've followed what's been happening with the marijuana legalization movement for years.

    In these parts, it's difficult to avoid - you see lots of folks walking around wearing their official Oaksterdam t-shirts.

    Since California legalized medical marijuana in 1996, another 19 states have joined the movement.

    The San Francisco-based market research firm ArcView Group estimates the national legal marijuana market at $1.53 billion in 2013. ArcView expects sales to nearly double to $2.57 billion by the end of this year.